KEY POINTS
- Rather than treating metformin simply as a direct tumor-cell drug, investigators examined whether it could modify the immunosuppressive glioblastoma microenvironment, particularly tumor-associated macrophages, and thereby enhance radiotherapy.
- In vitro effects were strongly context-dependent. Metformin partially reversed IL-4/IL-13-driven M2 polarization, but also dampened excessive LPS-driven inflammatory polarization. In glioblastoma-conditioned media it predominantly shifted macrophages away from the M2-like immunosuppressive state, leading the authors to describe its effect as restoration of macrophage “homeostasis” rather than simple M1 activation.
- These immune effects occurred at concentrations where direct tumor cytotoxicity was limited. After three days, 2 mM metformin suppressed CT-2A and MGPP3 tumor-cell growth by <10%, whereas much higher concentrations were required for 50% direct growth inhibition.
- In the orthotopic CT-2A model, mice received daily metformin with or without a single 8-Gy radiation treatment. Median survival was 34 days with RT alone versus 39 days with metformin + RT (p=0.02), and 3 of 15 mice (20%) in the combination group remained alive beyond 100 days without detectable recurrent tumor.
- The result was reproduced in a second syngeneic GL261 model: median survival reached 77.5 days with metformin + RT versus 37 days with RT alone and 28 days in controls, and 5 of 13 combination-treated mice survived beyond 100 days.
- Immune profiling provided a plausible mechanism. Metformin reduced CD206-positive tumor-associated macrophages, increased tumor CD8 T-cell infiltration and attenuated the RT-associated regulatory-T-cell signal. The combination increased the CD8/FoxP3 ratio by approximately 1.7-fold versus RT alone and reduced the RT-associated expansion of monocytic myeloid-derived suppressor cells.
- Peripheral immunity changed as well, with expansion of circulating CD4 and CD8 effector-memory T-cell populations. Importantly, these experiments used mouse-specific metformin doses and radiotherapy schedules and did not reproduce the full contemporary human glioblastoma treatment regimen, including concurrent temozolomide.
CLINICAL TAKEAWAY
The interesting finding is not simply that “metformin radiosensitizes glioblastoma,” but that it appears to reshape the immune consequences of irradiation, suppressing some immunosuppressive responses while preserving antitumor immunity. The reproducibility across two immunocompetent mouse models strengthens the biology, but this remains far from evidence that adding metformin improves outcomes in patients with glioblastoma.